The IEEE Engineering in Medicine and Biology Society’s 40th
International Conference is the first conference in which a
scientific track will be devoted to Tumor Treating Fields,
increasing the awareness of Novocure’s proprietary cancer therapy
among the scientific community
The conference will feature seven oral presentations on Tumor
Treating Fields
Novocure (NASDAQ: NVCR) announced today that a scientific track
has been dedicated to Tumor Treating Fields at the 40th
International Conference of the IEEE Engineering in Medicine and
Biology Society (EMBS), July 17 through July 21 in Honolulu,
Hawaii. Tumor Treating Fields is a cancer therapy that uses
electric fields tuned to specific frequencies to disrupt cell
division, inhibiting tumor growth and causing affected cancer cells
to die. The IEEE Engineering in Medicine and Biology Society’s 40th
International Conference is the first conference in which Tumor
Treating Fields will be featured in a dedicated scientific track,
increasing awareness of Novocure’s proprietary therapy among the
scientific community.
The track, “Computational Human Models V: Tumor Treating
Fields,” will feature six oral presentations and will be chaired by
Dr. Ze’ev Bomzon, Novocure’s Director of Science, and Dr. Eric T.
Wong, Associate Professor of Neurology at Harvard Medical School
and Co-Director of the Brain Tumor Center at Beth Israel Deaconess
Medical Center in Boston. An additional track will feature a
seventh oral presentation on Tumor Treating Fields by Novocure
Senior Physicist Dr. Cornelia Wenger, who will chair a track titled
“Computational Human Models VI: Emerging modeling and measurement
techniques.” Tumor Treating Fields is among a broad array of
scientific tracks covering diverse topics of cutting-edge research,
technology transfer and entrepreneurship, and biomedical
engineering education. Novocure also will present in a workshop on
energy-based cancer therapeutics.
“We are proud that EMBS has recognized Tumor Treating Fields as
an important area of concentration for the attendees of its
conference,” said Dr. Eilon Kirson, Novocure’s Chief Science
Officer and Head of Research and Development. “We believe the focus
of Tumor Treating Fields at this meeting will help generate
awareness and understanding of our therapy among the scientific
community. We look forward to participating in this scientific
exchange and educating the community on the science of our
therapy.”
Oral Presentations
(Abstract ThCT20.5) Connecting TTFields Distribution to Patient
Outcome: A Study Utilizing Simulations of TTFields Distributions in
Over 100 Patients (I). Z. Bomzon. 2:30 to 2:45 p.m. HST Thursday,
July 19.
(Abstract ThCT20.4) Insights from Computer Modeling: Analysis of
Physical Characteristics of Glioblastoma in Patients Treated with
TTFields (I). E. Wong. 2:15 to 2:30 p.m. HST Thursday, July 19.
(Abstract ThCT20.3) Estimating the Intensity and Anisotropy of
Tumor Treating Fields Using Matrix Decomposition towards a More
Comprehensive Estimation of Anti-Tumor Efficacy (I). A. Korshøj. 2
to 2:15 p.m. HST Thursday, July 19
(Abstract ThCT20.1) Advanced Multiparametric Imaging for
Response Assessment to TTFields in Patients with Glioblastoma (I)
S. Mohan. 1:30 to 1:45 p.m. HST Thursday, July 19.
(Abstract ThCT20.6) Simulating the Effect of 200 Khz AC Electric
Fields on Tumor Cell Structures to Uncover the Mechanism of a
Cancer Therapy (I). K. Carlson. 2:45 to 3 p.m. HST Thursday, July
19.
(Abstract ThCT20.2) Electroconductive Properties of
Microtubules, Actin and Kinesin (I) J. Tuszyński. 1:45 to 2 p.m.
HST Thursday July, 19.
(Abstract FrAT20.4) Water-Content Electrical Property Tomography
(wEPT) for Mapping Brain Tissues' Conductivity in the 100-1000 Khz
Range: Results of an Animal In-Vivo Study (I). C. Wenger. 8:45 to 9
a.m. HST Friday, July 20.
About IEEE Engineering in Medicine and Biology
Society
IEEE Engineering in Medicine and Biology Society is the world’s
largest international society of biomedical engineers. The
organization’s 12,000 members reside in some 97 countries around
the world. EMBS provides its members with access to the people,
practices, information, ideas and opinions that are shaping one of
the fastest growing fields in science.
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
Tumor Treating Fields, the use of electric fields tuned to specific
frequencies to disrupt solid tumor cancer cell division. Novocure’s
commercialized product is approved for the treatment of adult
patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating Tumor Treating Fields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 22, 2018, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180717005149/en/
Media and Investor Contact:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024